- Conditions
- Mixed Dyslipidemia
- Interventions
- ARO-ANG3, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- ARO-HIF2
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Las Vegas, Nevada • Nashville, Tennessee + 2 more
- Conditions
- Dyslipidemias
- Interventions
- ARO-APOC3
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • Northridge, California • Palm Springs, California + 24 more
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- zodasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Park Ridge, Illinois • New York, New York • Cincinnati, Ohio + 1 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Plozasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Plozasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Garden Grove, California • Lake Forest, California • Montclair, California + 42 more
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- ARO-ANG 3 Injection
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Mount Sinai, New York • Cincinnati, Ohio
- Conditions
- Familial Chylomicronemia
- Interventions
- Plozasiran, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 9
- States / cities
- Boca Raton, Florida • Suwanee, Georgia • Indianapolis, Indiana + 5 more
- Conditions
- Hypertriglyceridemia
- Interventions
- Plozasiran Injection
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 69
- States / cities
- Bakersfield, California • Beverly Hills, California • Canoga Park, California + 59 more
- Conditions
- Mixed Dyslipidemia
- Interventions
- ARO-APOC3, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Northridge, California • Boca Raton, Florida + 11 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- ARO-APOC3, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 33
- States / cities
- Beverly Hills, California • Palm Springs, California • Boca Raton, Florida + 26 more
- Conditions
- Chronic Hepatitis B
- Interventions
- ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- San Francisco, California • Miami, Florida • New York, New York + 1 more
- Conditions
- Hypertriglyceridemia
- Interventions
- Plozasiran Injection, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Plozasiran, Placebo
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Santa Clarita, California • New Haven, Connecticut + 14 more
- Conditions
- Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
- Interventions
- Plozasiran
- Drug
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 15 Years and older
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Fazisiran Injection, Placebo
- Drug · Other
- Lead sponsor
- Arrowhead Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more